ESR1 and breast cancer: Although this agonist activity is not attractive for ER+ breast cancer cases, it may be clinically relevant in other pathological conditions, such as neurodegenerative disorders, liver injuries, or cardiovascular diseases, where a beneficial action should not be ruled out [106,107].